The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of sickle cell disease and it typically involves excruciating, debilitating, episodic pain and can contribute to contribute to infection, stroke, multisystem organ damage, and shortened life expectancy. A type of VOC is ACS, which is one of the leading causes of death in these patients. Hypoxia, a low oxygen state in tissues, contributes to the underlying processes in both VOC and ACS. NVX-508 is designed to deliver oxygen to the diseased tissues in patients with sickle cell disease. Evan Unger MD, President and CEO of NuvOx Pharma said, “Acceptance of the IND is a major accomplishment for us. We can now proceed with clinical studies in this indication.”
To submit your application for funding to Desert Angels in a way that will bring it to our immediate attention, please click here.
Joann MacMaster was elected to be the Chief Executive Officer of Desert Angels, Inc. in January 2020. Prior to taking on the CEO role with Desert Angels, MacMaster served as the Sr. Director of Venture Development for the University of Arizona’s TLA team, focused on the commercialization of university research through the development of startup companies. She has served as a startup founder, mentor, investor, and educator, and is a recipient of the Larry Hecker and Sherry Hoskinson Lasting Community Builder Award. She is an AUTM board member and UA Academic Leadership Institute Fellow and previously served as President of the Arizona Business Incubation Association. She returned home to Tucson in 2000 after living and working in Europe for over a decade and holds an MBA from Edinburgh University Scotland.
For reasons other than Applying to Desert Angels, if you would like to communicate with Joann for other reasons or receive an update on your funding request, you can email Joann by clicking Contact our CEO.
